Johnson & Johnson's single-dose coronavirus vaccine is effective at preventing moderate and severe cases of COVID-19, according to an analysis of the trial data published by the Food and Drug Administration on Wednesday.
The company's single dose vaccine is 66 percent effective, well within the agency's standards. The vaccine is also safe to use, according to the analysis.
More specifically, the vaccine is more than 85 percent effective at preventing severe cases of COVID-19 and completely prevents hospitalizations and deaths.
Overall, there were seven deaths in the trial, all in the placebo group.
Join BJL on WhatsApp Status: Click here to Join BJL status for engagements, births, deals, levayos, events & more
Join BJL on WhatsApp Groups: Click here to Join an official BJL WhatsApp group for breaking news as it happens
The company initially announced the 66 percent effectiveness in a press release last month but had not yet released trial results.
The information was published ahead of an FDA advisory committee meeting Friday, which will debate whether to grant the vaccine emergency authorization. The promising data gives hope that a third coronavirus vaccine could be authorized as soon as this weekend.
While the other coronavirus vaccines already on the market may appear to be more effective than Johnson & Johnson's, experts say it is difficult to compare them head-to-head.
The vaccine was tested in a 44,000-person clinical trial across the U.S., Brazil and South Africa geographic regions, all of which have seen mutated versions of the virus. Read more at The Hill